Citation: | LINFei, HUANGDan, CHENTing-ting, YANGHan, CUIShu-na, LIShi-hua. Mechanisms of Combination ofAstragali Radix andSpatholobi Caulis in Treatment of Leukopenia Based on Network Pharmacology[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(6): 882-887. |
[1] |
马晓兰, 陶可胜, 李静. 肿瘤化疗后白细胞减少症的中西医治疗进展[J]. 中国当代医药, 2015, 22(8): 16-19.
|
[2] |
张淼, 田劭丹, 刘莉, 等. 恶性肿瘤患者体质特点及化疗后白细胞减少症体质原因分析[J]. 吉林中医药, 2017, 37(1): 14-18.
|
[3] |
赵磊, 江科, 陆清, 等. 中药治疗乳腺癌化疗致白细胞减少症的研究现状[J]. 上海中医药大学学报, 2013, 27(3): 118-122.
|
[4] |
李虹, 张蓉蓉. 中药复方治疗白细胞减少症用药规律分析[J]. 中医杂志, 2015, 56(4): 338-341.
|
[5] |
崔树娜, 胡雪琴, 温先荣. 基于关联规则挖掘的白细胞减少症方药规律分析[J]. 中国中医药图书情报杂志, 2014, 38(1): 23-26.
|
[6] |
高学敏.中药学[M]. 2版. 北京:中国中医药出版社,2012: 54.
|
[7] |
周龙云, 田子睿, 刘书芬, 等. 黄芪对中枢神经系统的药理作用及毒理研究现状[J]. 中草药, 2018, 49(20): 4935-4944.
|
[8] |
蒋微, 蒋式骊, 刘平. 黄芪甲苷的药理作用研究进展[J]. 中华中医药学刊, 2019, 37(9): 2121-2124.
|
[9] |
LIU C, WANG KJ, ZHUANG J, et al. The modulatory properties ofAstragalus membranaceus treatment on triple-negative breast cancer: An integrated pharmacological method[J]. Front Pharmacol, 2019, 10: 1171.
|
[10] |
姜辉, 顾胜龙, 张玉婷, 等. 黄芪化学成分和药理作用研究进展[J]. 安徽中医药大学学报, 2020, 39(5): 93-96.
|
[11] |
LIU X, WANG B, SUN Y, et al.Astragalus root extract inhibits retinal cell apoptosis and repairs damaged retinal neovascularization in retinopathy of prematurity[J]. Cell Cycle, 2019, 18(22): 3147-3159.
|
[12] |
LEE D, LEE D, CHOI S, et al. Identification and isolation of active compounds fromAstragalus membranaceus that improve insulin secretion by regulating pancreatic β-cell metabolism[J]. Biomolecules, 2019, 9(10): 618.
|
[13] |
LI WK, WANG GF, WANG TM, et al. Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice[J]. Phytomedicine, 2019, 62: 152948.
|
[14] |
官杰, 冯兴中, 刘剑刚. 鸡血藤防治动脉硬化相关药理作用的研究进展[J]. 中药新药与临床药理, 2019, 30(3): 385-389.
|
[15] |
杨冉冉, 刘新, 姬蕾, 等. 鸡血藤质量控制及药理作用研究进展[J]. 环球中医药, 2018, 11(11): 1833-1838.
|
[16] |
ZHANG CH, LIU JY, HE XY, et al. Caulis spatholobi ameliorates obesity through activating brown adipose tissue and modulating the composition of gut microbiota[J]. Int J Mol Sci, 2019, 20(20): 5150.
|
[17] |
LIM H, PARK M, KIM C, et al. MiR-657/ATF2 signaling pathway has a critical role inSpatholobus suberectus dunn extract-induced apoptosis in U266 and U937 cells[J]. Cancers, 2019, 11(2): 150.
|
[18] |
齐晓甜, 张家祥, 张晓亮, 等. 中药治疗化疗致白细胞减少症的研究进展[J]. 中草药, 2019, 50(20): 5088-5095.
|
[19] |
张喜平, 张翔, 杨红健, 等. 多种复方中药注射液治疗小鼠化疗相关白细胞减少症[J]. 中国临床药理学与治疗学, 2018, 23(10): 1116-1125.
|
[20] |
齐晓甜, 张家祥, 张晓亮, 等. 中药治疗化疗致白细胞减少症的研究进展[J]. 中草药, 2019, 50(20): 5088-5095.
|
[21] |
SPRINGUEL L, RENAULD JC, KNOOPS L. JAK kinase targeting in hematologic malignancies: A sinuous pathway from identification of genetic alterations towards clinical indications[J]. Haematologica, 2015, 100(10): 1240-1253.
|
[22] |
VAINCHENKER W, CONSTANTINESCU SN. JAK/STAT signaling in hematological malignancies[J]. Oncogene, 2013, 32(21): 2601-2613.
|
[23] |
AKADA H, AKADA S, HUTCHISON RE, et al. Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells[J]. Stem Cells, 2014, 32(7): 1878-1889.
|
[24] |
田瑞雪, 孙耀宗, 姚有昊, 等. 槲皮素对免疫低下小鼠免疫功能的影响[J]. 中国现代医药杂志, 2019, 21(9): 13-16.
|
[25] |
蒋蕊, 考书娟, 徐小娟, 等. 槲皮素对免疫低下小鼠体液免疫功能的影响[J]. 青岛农业大学学报(自然科学版), 2011, 28(2): 118-120, 125.
|
[26] |
杨凤华, 康成, 李淑华, 等. 黄芪水溶性黄酮类对小鼠细胞免疫功能的影响[J]. 时珍国医国药, 2002, 13(12): 718-719.
|
[27] |
谭潇. 基于抗氧化和促造血双重调控作用研究鸡血藤及其活性单体儿茶素的抗辐射机制[D]. 北京: 中国人民解放军医学院, 2016.
|
[28] |
夏涛, 高丽萍. 类黄酮及茶儿茶素生物合成途径及其调控研究进展[J]. 中国农业科学, 2009, 42(8): 2899-2908.
|
[29] |
彭仕友, 何小解, 易著文, 等. 微囊化儿茶素对环磷酰胺致免疫低下小鼠的免疫调节作用[J]. 中国组织工程研究与临床康复, 2009, 13(21): 4123-4127.
|
[30] |
杨宇清. 木瓜苷和儿茶素对小鼠细胞免疫功能的调节作用[D]. 合肥: 安徽医科大学, 2008.
|
[31] |
余洁, 彭哲, 谢婷, 等. 木犀草素对哮喘患儿外周血单核细胞TNF-α和IL-6分泌的影响及机制研究[J]. 中国免疫学杂志, 2019, 35(13): 1580-1583, 1589.
|
[32] |
曲国欣, 纪志华, 付昆, 等. 木犀草素通过调节PI3K/AKT/NF-κB信号通路对骨肉瘤U2OS细胞EMT转化和细胞生物学行为的影响[J]. 海南医学院学报, 2019, 25(21): 1601-1606.
|
[33] |
慕静静. 山柰酚对小鼠免疫功能的影响及对海仁酸致痫小鼠的免疫调节作用[D]. 广州: 暨南大学, 2010.
|
[34] |
侯敬申, 梁颖涛, 王伟雄, 等. 山柰酚抑制人胆囊癌细胞增殖及其对mTORC1通路的影响[J]. 暨南大学学报(自然科学与医学版), 2019, 40(5): 419-425.
|
[35] |
王琼, 刘爱军, 韦立新. 子宫内膜异位症相关卵巢恶性肿瘤病理研究进展[J]. 解放军医学院学报, 2017, 38(1): 89-91, 95.
|
[36] |
KOSTOPOULOU O, HOLZHAUSER S, LANGE B, et al. Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines[J]. Int J Oncol, 2019,55(6):4896.
|
[37] |
SHADEN MH, REHAM AHAE, AHMED AA, et al. PIK3CA polymorphism (rs17849079 C/T) and expression in breast cancer patients[J]. Gene Reports, 2019, 17: 100512.
|
[38] |
SCLAFANI F, WILSON SH, CUNNINGHAM D, et al. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients[J]. Int J Cancer, 2020, 146(1): 94-102.
|
[39] |
OGASAWARA A, HIHARA T, SHINTANI D, et al. Evaluation of circulating tumor DNA in patients with ovarian cancer harboring somaticPIK3CA orKRAS mutations[J/OL]. Cancer Res Treat[2020-09-06].DOI: 10.4143/crt.2019.688.
|
[40] |
MATSUMOTO T, YAMAZAKI M, TAKAHASHI H, et al. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas[J]. Am J Clin Pathol, 2015, 144(3): 452-463.
|